Episurf Medical (NASDAQ: EPIS B) announces that the first patient who received an Episealer® knee implant has been on a 5-year follow-up visit. A video from that visit is now available on Episurf Medical's website.
Nicolas Martinez Carranza, MD, PhD, performed the very first surgery with the Episealer® knee implant in 2012, after 4 years of pre-clinical research that formed the basis for the development of the implant and associated surgical instruments. In October this year, clinical follow-up and function tests were performed on this first patient.
"I am pleased to note that during the 5-years’ follow-up visit of the first patient who received an Episealer®, we saw results that few believed were possible when we started the first pre-clinical trial almost 10 years ago. The results show that this technology can be a very good option for those patients who are in the treatment gap where the options for us orthopaedic surgeons have been very limited." comments Dr Martinez Carranza.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.